Lisanti Capital Growth LLC Purchases Shares of 42,975 Palvella Therapeutics, Inc. $PVLA

Key Points

• Lisanti Capital Growth purchased 42,975 Palvella Therapeutics shares worth approximately $6.6 million, making PVLA about 1.4% of its portfolio and giving the fund roughly 0.30% ownership. Institutional investors collectively own 40.11% of the company.
• Palvella reported a quarterly loss of $1.52 per share, missing analysts’ expected loss of $1.17. Shares opened at $149.96, near their 12-month high of $161.38.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and average price target of $209.14, although COO Kathleen Goin sold 4,302 shares under a pre-arranged trading plan.

Lisanti Capital Growth LLC purchased a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 42,975 shares of the company's stock, valued at approximately $6,567,000. Palvella Therapeutics comprises about 1.4% of Lisanti Capital Growth LLC's investment portfolio, making the stock its 21st largest position. Lisanti Capital Growth LLC owned approximately 0.30% of Palvella Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. KBC Group NV purchased a new position in shares of Palvella Therapeutics during the first quarter valued at approximately $28,000. Group One Trading LLC lifted its stake in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company's stock worth $35,000 after acquiring an additional 200 shares during the period. Russell Investments Group Ltd. bought a new stake in Palvella Therapeutics in the third quarter valued at $36,000. JPMorgan Chase & Co. boosted its holdings in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock valued at $73,000 after acquiring an additional 3,242 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Palvella Therapeutics during the 2nd quarter valued at $85,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the firm's stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46. Following the completion of the transaction, the chief operating officer owned 2,154 shares of the company's stock, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company's stock.

Palvella Therapeutics Trading Down 0.3%

Shares of PVLA stock opened at $149.96 on Thursday. The company's fifty day moving average price is $140.96 and its 200-day moving average price is $123.87. The stock has a market cap of $2.16 billion, a PE ratio of -31.05 and a beta of -0.17. Palvella Therapeutics, Inc. has a 12 month low of $46.08 and a 12 month high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). On average, sell-side analysts forecast that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on PVLA. Truist Financial set a $207.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. HC Wainwright reissued a "buy" rating and issued a $270.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Finally, Chardan Capital upgraded shares of Palvella Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Palvella Therapeutics presently has an average rating of "Buy" and an average target price of $209.14.

About Palvella Therapeutics

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source